Motivated by the resurgence of pertussis and the limitations of the current aP vaccines, several research groups involved in the design of more effective third generation pertussis vaccines are focusing on nasal-delivery approaches that induce respiratory TRM cells and mucosal IgA, as well as circulating antibodies. The gene discussed is CD79A; the disease is pertussis.